Keytruda Small Cell Lung Cancer

On june 17 2019 the food and drug administration granted accelerated approval to pembrolizumab keytruda merck for patients with metastatic small cell lung cancer sclc with disease.

Keytruda small cell lung cancer.

Merck co s keytruda may be the star in non small cell lung cancer but a combo of it and chemo just failed to significantly outdo chemo alone at prolonging patients lives in small cell. While these reviews might be helpful they are not a substitute for the expertise knowledge and judgement of healthcare practitioners. Keytruda is a prescription medicine used to treat a kind of lung cancer called non small cell lung cancer nsclc. The following information is not intended to endorse any particular medication.

Keytruda may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread advanced nsclc and is a type called nonsquamous and your tumor does not have an abnormal egfr or alk gene. Keytruda pembrolizumab is used to treat advanced melanoma non small cell lung cancer small cell lung cancer head and neck squamous cell carcinoma classical hodgkin lymphoma primary mediastinal large b cell lymphoma urothelial carcinoma microsatellite instability high cancer gastric cancer esophageal cancer cervical cancer hepatocellular carcinoma merkel cell carcinoma renal cell. Keytruda is already an established treatment option for non small cell lung cancer and this approval in small cell lung cancer demonstrates our commitment to bringing forward new treatment.